Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Michael Heuser; Neil Palmisiano; Ioannis Mantzaris; Alice Mims; Courtney DiNardo; Lewis R. Silverman; Eunice S. Wang; Walter Fiedler; Claudia Baldus; Sebastian Schwind; Timothy Pardee; Alexander E. Perl; Charles Cai; Stefan Kaulfuss; Eleni Lagkadinou; Christine Rentzsch; Markus Wagner; Gary Wilkinson; Bingyan Wu; Michael Jeffers; Isabelle Genvresse; Alwin Krämer

doi:10.1038/s41375-020-0996-5

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Michael Heuser, Neil Palmisiano, Ioannis Mantzaris, Alice Mims, Courtney DiNardo, Lewis R. Silverman, Eunice S. Wang, Walter Fiedler, Claudia Baldus, Sebastian Schwind, Timothy Pardee, Alexander E. Perl, Charles Cai, Stefan Kaulfuss, Eleni Lagkadinou, Christine Rentzsch, Markus Wagner, Gary Wilkinson, Bingyan Wu, Michael JeffersIsabelle Genvresse, Alwin Krämer

Oncology

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses ranging from 300 to 1500 mg twice-daily. BAY1436032 exhibited a relatively short half-life and apparent non-linear pharmacokinetics after continuous dosing. Most subjects experienced only partial target inhibition as indicated by plasma R-2HG levels. BAY1436032 was safe and a maximum tolerated dose was not identified. The median treatment duration for all subjects was 3.0 months (0.49–8.5). The overall response rate was 15% (4/27; 1 CRp, 1 PR, 2 MLFS), with responding subjects experiencing a median treatment duration of 6.0 months (3.9–8.5) and robust R-2HG decreases. Thirty percent (8/27) achieved SD, with a median treatment duration of 5.5 months (3.1–7.0). Degree of R-2HG inhibition and clinical benefit did not correlate with dose. Although BAY1436032 was safe and modestly effective as monotherapy, the low overall response rate and incomplete target inhibition achieved at even the highest dose tested do not support further clinical development of this investigational agent in AML.

Original language	English (US)
Pages (from-to)	2903-2913
Number of pages	11
Journal	Leukemia
Volume	34
Issue number	11
DOIs	https://doi.org/10.1038/s41375-020-0996-5
State	Published - Nov 1 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41375-020-0996-5

Cite this

Heuser, M., Palmisiano, N., Mantzaris, I., Mims, A., DiNardo, C., Silverman, L. R., Wang, E. S., Fiedler, W., Baldus, C., Schwind, S., Pardee, T., Perl, A. E., Cai, C., Kaulfuss, S., Lagkadinou, E., Rentzsch, C., Wagner, M., Wilkinson, G., Wu, B., ... Krämer, A. (2020). Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 34(11), 2903-2913. https://doi.org/10.1038/s41375-020-0996-5

Heuser, M, Palmisiano, N, Mantzaris, I, Mims, A, DiNardo, C, Silverman, LR, Wang, ES, Fiedler, W, Baldus, C, Schwind, S, Pardee, T, Perl, AE, Cai, C, Kaulfuss, S, Lagkadinou, E, Rentzsch, C, Wagner, M, Wilkinson, G, Wu, B, Jeffers, M, Genvresse, I & Krämer, A 2020, 'Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results', Leukemia, vol. 34, no. 11, pp. 2903-2913. https://doi.org/10.1038/s41375-020-0996-5

@article{60636a410f20432681c06e7723ee7796,

title = "Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results",

abstract = "The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses ranging from 300 to 1500 mg twice-daily. BAY1436032 exhibited a relatively short half-life and apparent non-linear pharmacokinetics after continuous dosing. Most subjects experienced only partial target inhibition as indicated by plasma R-2HG levels. BAY1436032 was safe and a maximum tolerated dose was not identified. The median treatment duration for all subjects was 3.0 months (0.49–8.5). The overall response rate was 15% (4/27; 1 CRp, 1 PR, 2 MLFS), with responding subjects experiencing a median treatment duration of 6.0 months (3.9–8.5) and robust R-2HG decreases. Thirty percent (8/27) achieved SD, with a median treatment duration of 5.5 months (3.1–7.0). Degree of R-2HG inhibition and clinical benefit did not correlate with dose. Although BAY1436032 was safe and modestly effective as monotherapy, the low overall response rate and incomplete target inhibition achieved at even the highest dose tested do not support further clinical development of this investigational agent in AML.",

author = "Michael Heuser and Neil Palmisiano and Ioannis Mantzaris and Alice Mims and Courtney DiNardo and Silverman, {Lewis R.} and Wang, {Eunice S.} and Walter Fiedler and Claudia Baldus and Sebastian Schwind and Timothy Pardee and Perl, {Alexander E.} and Charles Cai and Stefan Kaulfuss and Eleni Lagkadinou and Christine Rentzsch and Markus Wagner and Gary Wilkinson and Bingyan Wu and Michael Jeffers and Isabelle Genvresse and Alwin Kr{\"a}mer",

note = "Publisher Copyright: {\textcopyright} 2020, The Author(s).",

year = "2020",

month = nov,

day = "1",

doi = "10.1038/s41375-020-0996-5",

language = "English (US)",

volume = "34",

pages = "2903--2913",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Safety and efficacy of BAY1436032 in IDH1-mutant AML

T2 - phase I study results

AU - Heuser, Michael

AU - Palmisiano, Neil

AU - Mantzaris, Ioannis

AU - Mims, Alice

AU - DiNardo, Courtney

AU - Silverman, Lewis R.

AU - Wang, Eunice S.

AU - Fiedler, Walter

AU - Baldus, Claudia

AU - Schwind, Sebastian

AU - Pardee, Timothy

AU - Perl, Alexander E.

AU - Cai, Charles

AU - Kaulfuss, Stefan

AU - Lagkadinou, Eleni

AU - Rentzsch, Christine

AU - Wagner, Markus

AU - Wilkinson, Gary

AU - Wu, Bingyan

AU - Jeffers, Michael

AU - Genvresse, Isabelle

AU - Krämer, Alwin

PY - 2020/11/1

Y1 - 2020/11/1

N2 - The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses ranging from 300 to 1500 mg twice-daily. BAY1436032 exhibited a relatively short half-life and apparent non-linear pharmacokinetics after continuous dosing. Most subjects experienced only partial target inhibition as indicated by plasma R-2HG levels. BAY1436032 was safe and a maximum tolerated dose was not identified. The median treatment duration for all subjects was 3.0 months (0.49–8.5). The overall response rate was 15% (4/27; 1 CRp, 1 PR, 2 MLFS), with responding subjects experiencing a median treatment duration of 6.0 months (3.9–8.5) and robust R-2HG decreases. Thirty percent (8/27) achieved SD, with a median treatment duration of 5.5 months (3.1–7.0). Degree of R-2HG inhibition and clinical benefit did not correlate with dose. Although BAY1436032 was safe and modestly effective as monotherapy, the low overall response rate and incomplete target inhibition achieved at even the highest dose tested do not support further clinical development of this investigational agent in AML.

AB - The mutant IDH1 (mIDH1) inhibitor BAY1436032 demonstrated robust activity in preclinical AML models, supporting clinical evaluation. In the current dose-escalation study, BAY1436032 was orally administered to 27 mIDH1 AML subjects across 4 doses ranging from 300 to 1500 mg twice-daily. BAY1436032 exhibited a relatively short half-life and apparent non-linear pharmacokinetics after continuous dosing. Most subjects experienced only partial target inhibition as indicated by plasma R-2HG levels. BAY1436032 was safe and a maximum tolerated dose was not identified. The median treatment duration for all subjects was 3.0 months (0.49–8.5). The overall response rate was 15% (4/27; 1 CRp, 1 PR, 2 MLFS), with responding subjects experiencing a median treatment duration of 6.0 months (3.9–8.5) and robust R-2HG decreases. Thirty percent (8/27) achieved SD, with a median treatment duration of 5.5 months (3.1–7.0). Degree of R-2HG inhibition and clinical benefit did not correlate with dose. Although BAY1436032 was safe and modestly effective as monotherapy, the low overall response rate and incomplete target inhibition achieved at even the highest dose tested do not support further clinical development of this investigational agent in AML.

UR - http://www.scopus.com/inward/record.url?scp=85088808939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088808939&partnerID=8YFLogxK

U2 - 10.1038/s41375-020-0996-5

DO - 10.1038/s41375-020-0996-5

M3 - Article

C2 - 32733012

AN - SCOPUS:85088808939

SN - 0887-6924

VL - 34

SP - 2903

EP - 2913

JO - Leukemia

JF - Leukemia

IS - 11

ER -

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this